摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

四氢-2H-吡喃-3-羧酰胺 | 18729-21-0

中文名称
四氢-2H-吡喃-3-羧酰胺
中文别名
——
英文名称
tetrahydropyran-3-carboxamide
英文别名
tetrahydro-2H-pyran-3-carboxamide;oxane-3-carboxamide
四氢-2H-吡喃-3-羧酰胺化学式
CAS
18729-21-0
化学式
C6H11NO2
mdl
——
分子量
129.159
InChiKey
KHDGSULFSVLOPM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    312.1±31.0 °C(Predicted)
  • 密度:
    1.114±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.6
  • 重原子数:
    9
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.83
  • 拓扑面积:
    52.3
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 危险等级:
    IRRITANT

反应信息

  • 作为反应物:
    描述:
    四氢-2H-吡喃-3-羧酰胺 、 4,5-dichloro-2-[4-(N-ethyl-4-fluoroanilino)phenyl]pyridazin-3-one 在 [(2-di-tert-butylphosphino-2′,4′,6′-triisopropyl-1, 1′-biphenyl)-2-(2′-amino-1,1′-biphenyl)] palladium(II) methanesulfonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下, 以 1,4-二氧六环 为溶剂, 生成 (3R)-N-[5-chloro-1-[4-(N-ethyl-4-fluoroanilino)phenyl]-6-oxopyridazin-4-yl]tetrahydropyran-3-carboxamide 、 (3S)-N-[5-chloro-1-[4-(N-ethyl-4-fluoroanilino)phenyl]-6-oxopyridazin-4-yl]tetrahydropyran-3-carboxamide
    参考文献:
    名称:
    [EN] PYRIDAZINONE DERIVATIVES USEFUL AS T CELL ACTIVATORS
    [FR] DÉRIVÉS DE PYRIDAZINONE UTILES EN TANT QU'ACTIVATEURS DE LYMPHOCYTES T
    摘要:
    Disclosed herein are oxime compounds having the structure of Formula (I'): or a pharmaceutically acceptable salt, solvate, hydrate, isomer, tautomer, racemate, or isotope thereof, wherein L1, L2, R1, R2, R3, R4, R7, n, and r are as defined herein. Pharmaceutical compositions comprising them, processes for preparing them and uses of them to treat or prevent diseases, disorders and conditions are also provided. The compounds are inhibitors of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ) and are useful in the treatment of diseases, disorders and conditions related to DGKα and / or DGKζ activity. In particular, the compounds are useful for treating viral infections and proliferative disorders, such as cancer.
    公开号:
    WO2023122778A1
点击查看最新优质反应信息

文献信息

  • INHIBITORS OF INFLUENZA VIRUSES REPLICATION
    申请人:Charifson Paul S.
    公开号:US20120171245A1
    公开(公告)日:2012-07-05
    Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
    抑制生物样本或患者中流感病毒的复制、减少生物样本或患者中流感病毒量以及治疗患者流感的方法,包括向所述生物样本或患者施用有效量的由结构公式(I)表示的化合物: 或其药用可接受盐,其中结构公式(IA)的值如本文所述。由结构公式(IA)或其药用可接受盐表示的化合物,其中结构公式(IA)的值如本文所述。药物组合物包括有效量的上述化合物或其药用可接受盐,以及药用可接受载体、佐剂或车辆。
  • NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES
    申请人:Merck Patent GmbH
    公开号:US20160168090A1
    公开(公告)日:2016-06-16
    The present invention relates to indole compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.
    本发明涉及吲哚化合物及其药用可接受的组合物,用作P2X7拮抗剂,用于治疗与P2X7相关的疾病。
  • [EN] 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS<br/>[FR] 1H-BENZIMIDAZOLE-5-CARBOXAMIDES COMME AGENTS ANTI-INFLAMMATOIRES
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2010034796A1
    公开(公告)日:2010-04-01
    There are provided compounds of formula (I), wherein R1, R6, R8, Q2, Q3, Q3a, Q4, L and A have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation and/or cancer.
    提供了具有式(I)的化合物,其中R1、R6、R8、Q2、Q3、Q3a、Q4、L和A的含义如描述中所给,并且其药学上可接受的盐,这些化合物在治疗需要或期望抑制MAPEG家族成员活性的疾病方面是有用的,特别是在炎症和/或癌症的治疗中。
  • [EN] CINNOLINES AS INHIBITORS OF HPK 1<br/>[FR] CINNOLINES UTILISÉES COMME INHIBITEURS DE HPK 1
    申请人:NANJING ZHENGXIANG PHARMACEUTICALS CO LTD
    公开号:WO2021004535A1
    公开(公告)日:2021-01-14
    Compounds of Formula (I) or (Ia), pharmaceutically acceptable salts, stereoisomers, tautomers, solvates or prodrugs, and their use as HPK1 inhibitors are described herein, and also described are methods for preparing the compounds, and methods of treating HPK1-dependent diseases or disorders, such as cancer.
    本文描述了化学式(I)或(Ia)的化合物,药用盐,立体异构体,互变异构体,溶剂合物或前药,以及它们作为HPK1抑制剂的用途,还描述了制备这些化合物的方法,以及治疗HPK1依赖性疾病或疾病的方法,如癌症。
  • METHOD FOR PRODUCING OPTICALLY ACTIVE 3-AMINOPIPERIDINE OR SALT THEREOF
    申请人:Mori Kohei
    公开号:US20100105917A1
    公开(公告)日:2010-04-29
    The present invention relates to a method for producing an optically active 3-aminopiperidine or salt thereof. In the method, a racemic nipecotamide is stereoselectively hydrolyzed to obtain an optically active nipecotamide and an optically active nipecotic acid in the presence of an enzyme source derived from an organism, and then the optically active nipecotamide is derived into an optically active aminopiperidine or salt thereof by aroylation, Hofmann rearrangement, deprotection of the amino group and further deprotection; or the optically active nipecotamide is derived into an optically active aminopiperidine or salt thereof by selective protection with BOC, Hofmann rearrangement and further deprotection. It is possible by the present invention to produce an optically active 3-aminopiperidine or salt thereof useful as a pharmaceutical intermediate from an inexpensive and easily available starting material by easy method applicable to industrial manufacturing.
    本发明涉及一种生产光学活性3-氨基哌啶或其盐的方法。在该方法中,通过在有机体衍生的酶源存在下,立体选择性解一个混合的尼皮科酰胺来获得光学活性尼皮科酰胺和光学活性尼皮科酸,然后通过酰化、霍夫曼重排、基保护基的去除和进一步的去保护,将光学活性尼皮科酰胺转化为光学活性哌啶或其盐;或者通过用BOC进行选择性保护、霍夫曼重排和进一步的去保护,将光学活性尼皮科酰胺转化为光学活性哌啶或其盐。通过本发明,可以从廉价且易得的起始材料中通过简单的工业制造方法生产出一种作为药物中间体有用的光学活性3-氨基哌啶或其盐。
查看更多

同类化合物

(3S,4R)-3-氟四氢-2H-吡喃-4-胺 鲁比前列素中间体 顺式-3-溴<2-(2)H>四氢吡喃 顺-4-氨基四氢吡喃-3-醇 顺-4-(四氢吡喃-2-氧)-2-丁烯-1-醇 顺-3-Boc-氨基-四氢吡喃-4-羧酸 锡烷,三丁基[3-[(四氢-2H-吡喃-2-基)氧代]-1-炔丙基]- 螺[金刚烷-2,2'-四氢吡喃]-4'-醇 蒿甲醚四氢呋喃乙酸酯 蒜味伞醇B 蒜味伞醇A 茉莉吡喃 苯基2,4-二氯-5-氨磺酰苯磺酸酯 苄基2,3-二-O-乙酰基-4-脱氧-4-C-硝基亚甲基-β-D-阿拉伯吡喃果糖苷 膜质菊内酯 红没药醇氧化物A 红没药醇氧化物 科立内酯 硅烷,(1,1-二甲基乙基)二甲基[[4-[(四氢-2H-吡喃-2-基)氧代]-5-壬炔基]氧代]- 甲磺酸酯-四聚乙二醇-四氢吡喃醚 甲基[(噁烷-3-基)甲基]胺 甲基6-氧杂双环[3.1.0]己烷-2-羧酸酯 甲基4-脱氧吡喃己糖苷 甲基3-脱氧-3-硝基-beta-L-核吡喃糖苷 甲基2,4,6-三脱氧-2,4-二-C-甲基吡喃葡己糖苷 甲基1,2-环戊烯环氧物 甲基-[2-吡咯烷-1-基-1-(四氢-吡喃-4-基)-乙基]-胺 甲基-(四氢吡喃-4-甲基)胺 甲基-(四氢吡喃-2-甲基)胺盐酸盐 甲基-(四氢吡喃-2-甲基)胺 甲基-(四氢-吡喃-3-基-胺 甲基-(四氢-吡喃-3-基)-胺盐酸盐 甲基-(4-吡咯烷-1-甲基四氢吡喃-4-基)-胺 甲基(5R)-3,4-二脱氧-4-氟-5-甲基-alpha-D-赤式-吡喃戊糖苷 环氧乙烷-2-醇乙酸酯 环己酮,6-[(丁基硫代)亚甲基]-2,2-二甲基-3-[(四氢-2H-吡喃-2-基)氧代]-,(3S)- 环丙基-(四氢-吡喃-4-基)-胺 玫瑰醚 独一味素B 溴-六聚乙二醇-四氢吡喃醚 氯菊素 氯丹环氧化物 氨甲酸,[[(四氢-2H-吡喃-2-基)氧代]甲基]-,乙基酯 氨甲酸,[(4-氨基四氢-2H-吡喃-4-基)甲基]-,1,1-二甲基乙基酯(9CI) 氧杂-3-碳酰肼 氧化氯丹 正-(四氢-4-苯基-2h-吡喃-4-基)乙酰胺 次甲霉素 A 桉叶油醇